|
 |
CV- Prof. Birkmayer
Prof. Georg D. Birkmayer, M.D., Ph. D. is a world-renowned biochemical researcher who was the first to identify the importance of NADH in cellular development and energy transmission for all bodily functions organs. He is the Medical Director of the Birkmayer Institute for Parkinson’s Therapy, which has treated thousands of patients suffering form Parkinson’s disease, Alzheimer’s disease and depression. Dr. Birkmayer is the author of more than 150 major research papers and more than 100 scientific articles in the area of cancer diagnosis, neurochemistry and neuropharmacology related to Parkinson and Alzheimer’s disease. He is a Professor at the University of Graz in Austria, heading its Division of Neurochemistry at the Department of Medicinal Chemistry. He is also a visiting Professor at the University of Beijing and Canton (China), Secretary General of the international Academy of Tumor Marker Oncology (New York). He is the European Editor of the Journal of Tumor Marker Oncology, and a member of the editorial board of the Journal of Experimental and Clinical Cancer Research and a number of other scientific journals. He is member of many international scientific societies such as the New Academy of Sciences, and the American Association of Cancer Research. He is also fellow of the American College of Nutrition.
The Birkmayer Contribution
A Legacy of Innovation in Healing
The story of NADH is intricately linked to the story of the Birkmayer family. It began in post war Vienna at the Hospital for the Brain Injured “Wiener Hirnverletzten-Lazarett”. There the young professor Walther Birkmayer saw over 3,000 brain injured patients as head physician. Grasping the importance of neuro-rehabilitation as a special discipline, he began a journey to explore the neurobiological reactive mechanisms within the brain. His observations led to the realization that injuries must create an imbalance between various reactor substances or neurotransmitters, resulting in a wide range of patient behaviours or symptoms.
His subsequent research with Parkinson’s patients during the late 50’s and early 60’s, using L-Dopa, the precursor to the substance dopamine, led to one of the crucially events of neurology. He succeeded in demonstration that a pharmacological effect could be counteracted by another chemical substance producing a specific physiological or physic result. In the years that followed, Dr. Walther Birkmayer was to receive four honorary Doctorates form leading European institutions in recognition of his outstanding lifetime contributions. He was also highly regarded by his patients for his help and his humanity.
Walther’s son Georg also became a doctor. After fighting at the forefront of cancer research, George was to follow his father, making his own contribution to the development of neuro-rehabilitative therapies. He went on to discover and implement the therapeutic usage of NADH or coenzyme 1.
In 1993, Dr. Georg Birkmayer, M. D., Ph. D., now also a renowned biochemical researcher an director of the Birkmayer Institute for Parkinson Therapy developed the first and only stable and absorbable oral tablets form of NADH. His discovery, recognized with worldwide patents, made NADH available to the general public as a nutritional supplement, licensed and only available under the brand name: good morning! enada®.
Research continues in the U.S.A. and abroad to explore good morning! enada®’s full potential. FDA approved clinical trials are currently being conducted under auspices of leading American research hospitals.
|
|
